Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma
Objective: This study aimed to evaluate the efficacy and safety of daratumumab as a maintenance treatment after autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with newly diagnosed multiple myeloma (NDMM) . Methods: The clinical data, hematological and renal response, and safety of 15 post-transplant patients with NDMM who had received daratumumab maintenance between May 1, 2022 and June 30, 2023 were retrospectively analyzed. Results: Fifteen patients (11 males and 4 females) with a median age of 58 (41-72) years were included. Thirteen patients did not receive daratumumab during induction therapy and auto-HSCT, 6 patients had renal impairment, and nine patients had high-risk cytogenetics. The median infusion of daratumumab was 12 (6-17) times, and the median duration of maintenance was 6 (1.5-12) months. The treatment efficacy was evaluated in all 15 patients, and daratumumab maintenance therapy increased the rate of stringent complete response from 40% to 60%. The renal response rate and median estimated glomerular filtration rate of six patients with RI-NDMM were also improved. During daratumumab maintenance therapy, the most common hematological grade 3 adverse event (AE) was lymphopenia [4 of 15 patients (26.67%) ], whereas the most common nonhematologic AEs were infusion-related reactions [7 of 15 patients (46.67%) ] and grade 3 pneumonia [5 of 15 patients (33.33%) ]. The five patients with pneumonia were daratumumab naive [5 of 13 patients (38.46%) ], with a median of 8 (6-10) infusions. Among them, the chest computed tomography of three patients showed interstitial infiltrates, and treatment with methylprednisolone was effective. With a median follow-up of 12 months, the 1-year overall survival rate was 93.33%, and only one patient died (which was not related to daratumumab treatment) . Conclusions: Daratumumab was safe and effective as a maintenance agent for post-auto-HSCT patients with NDMM, and AEs were controllable. The most common nonhematologic AE was grade 3 pneumonia, and a less dose-intense maintenance regimen for the first 8 weeks could reduce the incidence of pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 44(2023), 12 vom: 14. Dez., Seite 1016-1021 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Ma, Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z63YK6E0E |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 21.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.issn.0253-2727.2023.12.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369931289 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369931289 | ||
| 003 | DE-627 | ||
| 005 | 20240322000819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.issn.0253-2727.2023.12.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369931289 | ||
| 035 | |a (NLM)38503525 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Ma, Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: This study aimed to evaluate the efficacy and safety of daratumumab as a maintenance treatment after autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with newly diagnosed multiple myeloma (NDMM) . Methods: The clinical data, hematological and renal response, and safety of 15 post-transplant patients with NDMM who had received daratumumab maintenance between May 1, 2022 and June 30, 2023 were retrospectively analyzed. Results: Fifteen patients (11 males and 4 females) with a median age of 58 (41-72) years were included. Thirteen patients did not receive daratumumab during induction therapy and auto-HSCT, 6 patients had renal impairment, and nine patients had high-risk cytogenetics. The median infusion of daratumumab was 12 (6-17) times, and the median duration of maintenance was 6 (1.5-12) months. The treatment efficacy was evaluated in all 15 patients, and daratumumab maintenance therapy increased the rate of stringent complete response from 40% to 60%. The renal response rate and median estimated glomerular filtration rate of six patients with RI-NDMM were also improved. During daratumumab maintenance therapy, the most common hematological grade 3 adverse event (AE) was lymphopenia [4 of 15 patients (26.67%) ], whereas the most common nonhematologic AEs were infusion-related reactions [7 of 15 patients (46.67%) ] and grade 3 pneumonia [5 of 15 patients (33.33%) ]. The five patients with pneumonia were daratumumab naive [5 of 13 patients (38.46%) ], with a median of 8 (6-10) infusions. Among them, the chest computed tomography of three patients showed interstitial infiltrates, and treatment with methylprednisolone was effective. With a median follow-up of 12 months, the 1-year overall survival rate was 93.33%, and only one patient died (which was not related to daratumumab treatment) . Conclusions: Daratumumab was safe and effective as a maintenance agent for post-auto-HSCT patients with NDMM, and AEs were controllable. The most common nonhematologic AE was grade 3 pneumonia, and a less dose-intense maintenance regimen for the first 8 weeks could reduce the incidence of pneumonia | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autologous stem cell transplantation | |
| 650 | 4 | |a Daratumumab | |
| 650 | 4 | |a Maintenance therapy | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Xiao, X B |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, X L |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, S Z |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, S H |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, G N |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Y Q |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, N N |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, P |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, M S |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, W R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi |d 1993 |g 44(2023), 12 vom: 14. Dez., Seite 1016-1021 |w (DE-627)NLM081873417 |x 0253-2727 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:12 |g day:14 |g month:12 |g pages:1016-1021 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.12.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 12 |b 14 |c 12 |h 1016-1021 | ||